Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ribavirin

FDA-approved product (for solution, inhalation), marketed as Copegus, Rebetol, Ribasphere and 2 more.

Registered studies
50+
Lab records
2
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Ribavirin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection
  • Cirrhosis of liver
  • Fibrosis
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antivirals for treatment of hcv infections
FDA pharmacologic class
Nucleoside Analog Antiviral FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP01; FDA class Nucleoside Analog Antiviral

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Ribavirin, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA19.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli5.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae5.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis22.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • E. coli: measured active in 0 of 1 lab record
  • K. pneumoniae: measured active in 0 of 1 lab record
Open Ribavirin in ChEMBL Registered studies below
Show the 2 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ribavirin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)

    NCT00686517 · start 2003-12

    Registered record
    Registry ID
    NCT00686517
    Conditions
    Hepatitis C
    Interventions
    Pegylated interferon alfa-2b; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-12
    Completion
    2010-12
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionPegylated interferon alfa-2b; Ribavirin
    PhasePhase 3
    Registry statusCompleted

  • Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C

    NCT00948220 · start 2003-07

    Registered record
    Registry ID
    NCT00948220
    Conditions
    Hepatitis C, Chronic; Liver Diseases; Virus Diseases
    Interventions
    peginterferon alfa-2a and ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-07
    Completion
    2008-03
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic; Liver Diseases; Virus Diseases
    Interventionpeginterferon alfa-2a and ribavirin
    PhasePhase 4
    Registry statusCompleted

  • Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC

    NCT00207363 · start 2002-02

    Registered record
    Registry ID
    NCT00207363
    Conditions
    Hepatitis C
    Interventions
    Ribavirin, Peg interferon alfa 2b; induction therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-02
    Completion
    2010-01
    Enrolment
    610

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionRibavirin, Peg interferon alfa 2b; induction therapy
    PhasePhase 4
    Registry statusCompleted

  • Ribavirin Compared With Standard Care in Treating Patients With Respiratory Syncytial Virus Following Stem Cell Transplantation

    NCT00016081 · start 1998-03

    Registered record
    Registry ID
    NCT00016081
    Conditions
    Infection
    Interventions
    ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1998-03
    Completion
    2003-03
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection
    Interventionribavirin
    PhasePhase 3
    Registry statusCompleted

  • Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection

    NCT00015652

    Registered record
    Registry ID
    NCT00015652
    Conditions
    HIV Infections; Hepatitis C
    Interventions
    Ribavirin; Aldesleukin; Peginterferon alfa-2b
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2005-03
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Hepatitis C
    InterventionRibavirin; Aldesleukin; Peginterferon alfa-2b
    PhaseNot applicable
    Registry statusCompleted